ClinicalTrials.gg
Active, not recruitingNCT03038568Updated Apr 22, 2026

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

An observational study in Colorectal Cancer Metastatic, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
169
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center — 12 open to participants now, 18 under way, none of them phase 3. Colorectal Neoplasms · Memorial Sloan Kettering Cancer Center.

Enrollment
8th of 21
169 · median 110
Started
2017
with 1 other
Observational
21 of 69
5 open now
Primary completion
2027-01
later than 3 of 17 live
Registered
52nd of 69
by date

Among the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 8th largest by enrollment of the 21 observational ones that give a count, is one of 2 that started in 2017, is one of 21 observational ones, reaches primary completion later than 3 of the 17 other live ones, and was the 52nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

12 of the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 6 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of the study is to see how measurements of tumor differences vary with slight changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even in the setting of variable scan parameters and variable contrast timing. Participants will be consented to undergo an additional CT of their abdomen.

03

Conditions studied

  • Colorectal Cancer Metastatic

Keywords

  • colorectal liver metastases
  • CT scan
  • 17-010
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who undergo contrast enhanced CT scanning for colorectal liver metastases will be consented for one additional CT abdomen phase during the same imaging session.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years of age on the day of signed
  • Patients scheduled and approved for contrast enhanced CT that includes imaging of the abdomen and pelvis following the Department of Radiology standard of care protocol as per local institutional guidelines
  • Patients with measurable colorectal liver on prior imaging, with at least one tumor greater than 2.0 cm in axial maximal diameter

Exclusion criteria

Exclusion Criteria:

  • Patient who is pregnant and/or lactating
  • Patient scheduled for CT that includes the abdomen with a multiphasic contrast enhanced protocol (e.g. Triple Phase or Quadruple Phase Liver CT)
  • Patient who require reduced intravenous contrast dose based on the Department of Radiology contrast policy as per local institutional guidelines
  • Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign , cooperate and participate in the study, or follow up procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
169 participants (actual)
Patient registry
No

Groups and cohorts

  • Cohort 1

    -15 second time gap between routine abdominal CT and add on CT, Noise Index of 12

    Diagnostic Test: CT scan

  • Cohort 2

    -15 second time gap between routine abdominal CT and add on CT, Noise Index of 14

    Diagnostic Test: CT scan

  • Cohort 3

    -15 second time gap between routine abdominal CT and add on CT, Noise Index of 16

    Diagnostic Test: CT scan

  • Cohort 4

    -10 second time gap between routine abdominal CT and add on CT, Noise index 12

    Diagnostic Test: CT scan

  • Cohort 5

    -10 second time gap between routine abdominal CT and add on CT, Noise index 14

    Diagnostic Test: CT scan

  • Cohort 6

    -10 second time gap between routine abdominal CT and add on CT, Noise index 16

    Diagnostic Test: CT scan

  • Cohort 7

    \- 5 second time gap between routine abdominal CT and add on CT, Noise index 12

    Diagnostic Test: CT scan

  • Cohort 8

    \- 5 second time gap between routine abdominal CT and add on CT, Noise index 14

    Diagnostic Test: CT scan

  • Cohort 9

    \- 5 second time gap between routine abdominal CT and add on CT, Noise index 16

    Diagnostic Test: CT scan

  • Cohort 10

    \+ 5 second time gap between routine abdominal CT and add on CT, Noise index 12

    Diagnostic Test: CT scan

  • Cohort 11

    \+ 5 second time gap between routine abdominal CT and add on CT, Noise index 14

    Diagnostic Test: CT scan

  • Cohort 12

    \+ 5 second time gap between routine abdominal CT and add on CT, Noise index 16

    Diagnostic Test: CT scan

  • Cohort 13

    \+ 10 second time gap between routine abdominal CT and add on CT, Noise index 12

    Diagnostic Test: CT scan

  • Cohort 14

    \+ 10 second time gap between routine abdominal CT and add on CT, Noise index 14

    Diagnostic Test: CT scan

  • Cohort 15

    \+ 10 second time gap between routine abdominal CT and add on CT, Noise index 16

    Diagnostic Test: CT scan

  • Cohort 16

    \+ 15 second time gap between routine abdominal CT and add on CT, Noise 12

    Diagnostic Test: CT scan

  • Cohort 17

    \+ 15 second time gap between routine abdominal CT and add on CT, Noise 14

    Diagnostic Test: CT scan

  • Cohort 18

    \+ 15 second time gap between routine abdominal CT and add on CT, Noise 16

    Diagnostic Test: CT scan

Interventions

  • Diagnostic testCT scan

    Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.

06

What researchers measure

Primary outcomes

  1. assess the stability (reproducibility) of radiomic measurements obtained from repeat abdominal CT scans

    There will be 18 cohorts, each cohort differing by the length of the time gap in acquisition and noise index. In addition each acquisition will be reconstructed in 21 different ways (combinations of 3 slice thicknesses and 7 ASiR levels).

    Time frame: 2 years

07

Study locations

2 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Jan 2027, 120 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 120 months is above that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2017
First posted
Jan 31, 2017
StartActual
Jan 27, 2017
Primary completionEst.
Jan 27, 2027
CompletionEst.
Jan 27, 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03038568
Collaborators
Queen's University
Responsible party
Sponsor
First posted
Jan 31, 2017
Start date
Jan 27, 2017
Primary completion
Jan 27, 2027 (estimated)
Completion
Jan 27, 2027 (estimated)
Last update
Apr 22, 2026

Study contacts

Kinh Gian Richard Do, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion